SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Curtis Frazier who wrote (20758)4/18/1999 3:54:00 PM
From: VLAD  Read Replies (2) of 23519
 
Curtis,

Another important facet that needs much improvement on Vivus is analyst coverage. Paine Webber is the only brokerage that has kept on course and continues active coverage. I have to give Charlie O credit for not giving up just because the stock price tanked.

So who quit coverage: Daine discontinued because the analyst who was covering vivus left the company. CS First Boston had to give up coverage and market making when they became Vivus' investment banker last August. Once this "relationship" ends, I am sure the will once again actively cover Vivus.

Who is left? First there is the bucket shop back stabber who bought into the Fulgham propaganda last June and downgraded vivus to a hold. Now he just sits on the side lines with his finger up his poop. Then there is Cruttendon Roth. With Fayemi's departure, the other analyst (Curtis Hogue) sort of "inherited" the job. He changed the rating from Wole's "arbitrage" rating to a hold and also has decided to sit on the side lines with his finger in his poop.

So who is really covering Vivus? Just Charlie O at Paine Webber.
The VLAD has reason to believe that several brokerages are now accumulating vivus stock before they make their announcement of initiating coverage in Vivus with a buy recommendation. after all, this is how the game is played. They don't issue a buy recommendation and then buy stock after a big run up. They look for value, potential, and study other factors such as how many dumb shorts have not covered on a company with great turn around potential and only AFTER establishing their position in that stock do they place their buy recommendation.

Don't under estimate our new CFO's connections to the Street. Look what he did in the past to turn around Novell.

The writing is on the wall on vivus.

Just like the longs who bought into vivus in the low to mid 20's late in 1997 only to be caught in a 9 point gap down, the same scenario will eventually happen to those establishing sub $6.00 short positions. They will be caught with their pants down on the gap up and then the manipulative mms will milk their golden cow as the price continues to appreciate.

Sit back and enjoy. Too much good news coming out for a small cap stock with a 20% short interest between now and the June 8 annual share holder's meeting not to watch with a smile on your face.

Scope, where are you? Bend over. VLAD has a present for you.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext